JP Morgan Chase
PLX icon

JP Morgan Chase’s Protalix BioTherapeutics PLX Stock Holding History

JP Morgan Chase’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.2K Buy
31,685
+811
+3% +$2.01K ﹤0.01% 6056
2025
Q4 		$55.6K Buy
30,874
+883
+3% +$1.8K ﹤0.01% 6187
2025
Q3 		$66.6K Sell
29,991
-4,554
-13% -$7.42K ﹤0.01% 6117
2025
Q2 		$51.1K Buy
34,545
+32,950
+2,066% +$67.4K ﹤0.01% 5921
2025
Q1 		$4.08K Hold
1,595
– – ﹤0.01% 6459
2024
Q4 		$3K Hold
1,595
– – ﹤0.01% 6586
2024
Q3 		$1.63K Hold
1,595
– – ﹤0.01% 6648
2024
Q2 		$1.87K Sell
1,595
-30,923
-95% -$36.5K ﹤0.01% 6537
2024
Q1 		$41K Sell
32,518
-11,216
-26% -$16.7K ﹤0.01% 6009
2023
Q4 		$77.8K Hold
43,734
– – ﹤0.01% 5843
2023
Q3 		$72.6K Sell
43,734
-1,026
-2% -$1.84K ﹤0.01% 5660
2023
Q2 		$89.5K Buy
+44,760
New +$107K ﹤0.01% 5516
2022
Q3 		– Sell
-395
Closed – – 6765
2022
Q2 		$0 Sell
395
-732
-65% -$856 ﹤0.01% 6783
2022
Q1 		$1K Buy
+1,127
New +$1.03K ﹤0.01% 6492
2021
Q4 		– Sell
-5,847
Closed -$8K – 6890
2021
Q3 		$8K Buy
+5,847
New +$8.89K ﹤0.01% 6197
2021
Q2 		– Sell
-1,293
Closed -$6K – 6555
2021
Q1 		$6K Sell
1,293
-807
-38% -$3.76K ﹤0.01% 5846
2020
Q4 		$8K Hold
2,100
– – ﹤0.01% 5411
2020
Q3 		$8K Buy
2,100
+2,000
+2,000% +$7.23K ﹤0.01% 5293
2020
Q2 		$0 Buy
+100
New +$342 ﹤0.01% 5617
2020
Q1 		– Sell
-100
Closed – – 5633
2019
Q4 		$0 Hold
100
– – ﹤0.01% 5829
2019
Q3 		$0 Hold
100
– – ﹤0.01% 5904
2019
Q2 		$0 Hold
100
– – ﹤0.01% 5945
2019
Q1 		$0 Hold
100
– – ﹤0.01% 5970
2018
Q4 		$0 Buy
+100
New +$475 ﹤0.01% 5876

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase's PLX Position: Q1 2026 in Review

JP Morgan Chase increased its Protalix BioTherapeutics (PLX) stake by 2.6% in Q1 2026, buying an estimated $2.01K and bringing the position to 31,685 shares worth $66.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6056.

JP Morgan Chase first reported a position in PLX in Q4 2018 and has held it in 24 quarters since. The position peaked at $89.5K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • JP Morgan Chase held 31,685 shares of Protalix BioTherapeutics worth $66.2K as of Q1 2026.
  • JP Morgan Chase bought 811 Protalix BioTherapeutics shares in Q1 2026, an estimated $2.01K.
  • Protalix BioTherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6056 holding.
  • JP Morgan Chase first reported a position in Protalix BioTherapeutics in Q4 2018 and has held it in 24 quarters since.
  • JP Morgan Chase's Protalix BioTherapeutics position peaked at $89.5K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.